Could a common diabetes pill boost dialysis outcomes?
NCT ID NCT07491042
First seen Mar 28, 2026 · Last updated Jun 13, 2026 · Updated 13 times
Summary
This study tests whether dapagliflozin, a drug usually used for diabetes, can help people with end-stage kidney disease on peritoneal dialysis remove more fluid and produce more urine. About 38 adults and teens will take the pill daily for six months. Researchers will check fluid removal, dialysis adequacy, and urine output at 3 and 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE CHRONIC RENAL FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jehad Badawi AL LAHAM
RECRUITINGNizwa, Oman
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.